Exoderm cream 1% 30g tube #1

Exoderil Cream 1% 30g tube Composition: Active substance per 1 gram - Naftifine hydrochloride 10 mg Excipients per 1 gram - Benzyl alcohol 0.010g, Cetyl alcohol 0.040g, Stearyl alcohol 0.040g. Therapeutic indications: Used for the treatment of the following conditions: Mycotic infections of the skin or skin folds (tinea corporis, tinea inguinalis) Athlete's foot (tinea manus, tinea pedis) Fungal nail infections (onychomycosis) Cutaneous candidiasis infections Pityriasis versicolor Inflammatory dermatophytosis (with or without itching). Dosage/frequency and duration of use: Skin infections: Exoderil should be applied in a thin layer to the affected skin area, preferably in the evening before bedtime, and gently rubbed in. With each application, it should be applied to the entire affected skin zone and a 2 cm area of healthy skin. In mycoses between skin folds, it is beneficial to place a thin gauze pad between the folds after applying the medication at night. Nail infections: The infected nail should be cut as close to the base as possible. Exoderil is used once a day and should be rubbed into the nail. It is advisable to bandage the affected nail. For the treatment to be successful, Exoderil should be prescribed for a sufficiently long period. To prevent recurrence of the disease, use should be continued for at least two weeks after the disappearance of symptoms. The duration of treatment may vary depending on the disease. General duration of use For dermatophytic infections 2-4 weeks In severe cases 4-8 weeks For superficial candidiasis 4 weeks For nail mycosis up to 6 months Treatment of Pityriasis versicolor may take 2 weeks. Method of use: The preparation is used topically. Before use, the affected skin or nail area should be washed with warm water and dried thoroughly. If no clinical improvement is observed after 4 weeks of starting treatment, the patient should undergo re-examination. Pregnancy: Clinical data on the use of naftifine during pregnancy are not available. Animal studies do not indicate direct or indirect harmful effects on pregnancy/embryonic/fetal development/birth or postnatal development. Caution is advised when using this preparation in pregnant women. Lactation: It is unknown whether naftifine is excreted in breast milk. Excretion of naftifine in milk has not been studied in animals. When deciding whether to stop treatment with Exoderil or breastfeeding, the benefits of breastfeeding for the child and maternal treatment with Exoderil should be assessed. Storage: It should be stored at a temperature not exceeding 25°C. Store in the original packaging and out of reach of children.